J B Chemicals & Pharmaceuticals Ltd
J B Chemicals & Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Domestic business expected to grow at 12% to 14% for the full year, with H2 picking up due to strong chronic segment growth. JB Pharma expects continued outperformance of the Indian pharma market with growth 300-400 bps above IPM volume growth.
From J B Chemicals & Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Domestic business expected to grow at 12% to 14% for the full year, with H2 picking up due to strong chronic segment growth.
- Chronic segment growing over 20%, supporting sustained volume growth.
- International formulations expected to see a recovery with high single-digit growth in H2, especially in markets like South Africa and the US.
- CDMO business projected to grow at 12% to 14% for the year, maintaining strong momentum from 20% growth in Q2.
- Volume growth in domestic business approximately 4%-5%, with price growth around 6%-7%.
- MR productivity target is to touch INR 8 lakh to justify future field force additions.
2 more points from J B Chemicals & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what J B Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for the entire year is expected to be close to INR 100 crore.
- Maintenance capex typically ranges between INR 60 crore to INR 65 crore annually.
- The greenfield capex this year primarily relates to a new IV line, which is expected to be commissioned within the next two months.
2 more points from J B Chemicals & Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what J B Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- JB Pharma has a robust pipeline of products lined up for their global partners.
- The order book remains strong for the second half of FY '26.
- The CDMO business, which is part of the international operations, reported a 20% year-on-year growth, supported by good sales momentum and a strong order book.
2 more points from J B Chemicals & Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
J B Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹904 Cr, net profit ₹101 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What J B Chemicals & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
J B Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were J B Chemicals & Pharmaceuticals Ltd Q2 FY26 results?
Domestic business expected to grow at 12% to 14% for the full year, with H2 picking up due to strong chronic segment growth. JB Pharma expects continued outperformance of the Indian pharma market with growth 300-400 bps above IPM volume growth.
What is J B Chemicals & Pharmaceuticals Ltd share price analysis?
J B Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.8 with a market cap of ₹38,677 Cr. Investors should review the full earnings analysis for detailed insights.
Is J B Chemicals & Pharmaceuticals Ltd planning capital expenditure?
Capex for the entire year is expected to be close to INR 100 crore.
Keep J B Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.